BACKGROUND: Despite its @entity137 , @entity900 every 3 weeks (q3w) is the standard potentiation of chemo-radiotherapy for @entity213 . This study aimed to determine whether weekly @entity900 (q1w) could be a safe and effective alternative. @entity1 AND METHODS: Two hundred and sixty-two @entity1 with @entity213 , irradiated in our institution with @entity900 (q1w or q3w) between January 2004 and December 2008, were retrospectively included. @entity1349 ( @entity1349 ) and progression-free survival (PFS) were evaluated. Survival distributions were estimated by Kaplan-Meier method and compared using the log-rank test. Prognostic effect of chemo-radiotherapy was explored using Cox model. RESULTS: A total of 165 and 97 @entity1 received q1w and q3w @entity900 , respectively. Median age, stage at diagnosis, @entity285 consumption, intensity-modulated radiation therapy use, median weight, and @entity177 before radiotherapy were significantly different, showing lower risk in the q3w group. Q3w @entity900 was found to be more toxic in terms of @entity353 , @entity177 , worse chemotherapy plan completion, and grade 3/4 @entity33 and @entity1909 , with more @entity1 requiring analgesics, secondary hospitalization, and radiotherapy interruption (>= 3 days), and @entity1 affected by long-term @entity137 . With a median follow-up of 73 months (95% confidence interval [CI] [68.9-76.2]), @entity1349 was found to be significantly better with q3w (5 years @entity1349 : 62.3%; 95% CI [51.6-71.3]) than with q1w @entity900 (5 years @entity1349 : 52.6%; 95% CI [44.5-60.0]) (log-rank P=0.0146). More number of @entity1 treated according to the q1w schedule experienced a recurrence: 47.3% vs 30.9% (P=0.009). Thus, the PFS for q3w schedule was found to be globally better (5 years PFS: 55.8%; 95% CI [45.0-65.3]) than for q1w schedule (5 years PFS: 43.6%; 95% CI [35.9-51.0]) (log-rank P=0.0161). However, both multivariate analyses, @entity1349 and PFS, produce no significant hazard ratio for chemo-radiotherapy modality once adjusted on unbalanced covariates according to the descriptive analysis. CONCLUSION: Though q1w seemed to be safer than q3w according to the descriptive analysis, multivariate analyses failed to conclude about its efficiency. Therefore, we conclude that the q3w schedule should remain the standard and prospective comparisons are needed.

Radiotherapy potentiation with weekly @entity900 compared to standard every 3 weeks @entity900 chemotherapy for locoregionally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity213 :: ('MESH:C535575', 'Disease') :: ['head and neck squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity285 :: ('D000431', 'Chemical') :: ['alcohol'] @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity213 :: (MESH:C535575,Disease) :: ['head and neck squamous cell carcinoma']
